Barlow Wealth Partners Inc. Acquires New Stake in Becton, Dickinson and Company (NYSE:BDX)

Barlow Wealth Partners Inc. acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 927 shares of the medical instruments supplier’s stock, valued at approximately $226,000.

A number of other institutional investors have also bought and sold shares of the business. OFI Invest Asset Management purchased a new position in Becton, Dickinson and Company during the third quarter worth approximately $25,000. DiNuzzo Private Wealth Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $30,000. Fortitude Family Office LLC purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $35,000. Venturi Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 552.0% during the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 138 shares during the last quarter. Finally, Arlington Trust Co LLC acquired a new stake in Becton, Dickinson and Company during the fourth quarter worth about $41,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 0.2 %

Shares of BDX stock traded up $0.56 during trading hours on Tuesday, hitting $237.14. The company had a trading volume of 1,120,070 shares, compared to its average volume of 1,408,706. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The stock has a market capitalization of $68.54 billion, a PE ratio of 52.23, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The company’s fifty day moving average is $238.27 and its 200 day moving average is $239.97. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period last year, the business posted $2.86 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Wall Street Analyst Weigh In

Separately, Barclays boosted their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average target price of $281.40.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Company insiders own 0.31% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.